Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 3/2011

01-03-2011 | Brief Report

Are we ready to use aliskiren in children?

Authors: Erin Elizabeth Kelland, Leanne Michelle McAuley, Guido Filler

Published in: Pediatric Nephrology | Issue 3/2011

Login to get access

Abstract

The objective of this case series was to review the safety and efficacy of aliskiren in combination with losartan in pediatric chronic kidney disease (CKD) patients. This was a retrospective study in which the medical files of all patients who had received aliskiren were reviewed. Four patients were identified between 5 and 18 years of age who had received aliskiren and losartan for the reduction of refractory proteinuria. While proteinuria was reduced in all four of these patients by 45, 96, 53, and 64%, respectively, three patients experienced side effects requiring changes in the aliskiren dose. A significant side effect occurred in the patient with CKD stage 3 who suffered accelerated loss of kidney function leading to dialysis after only a short course of therapy. The data from this preliminary trial strongly suggest that clinicians should exercise caution when prescribing aliskiren in combination with losartan until appropriate pediatric trials establish dosing, efficacy, and safety.
Literature
1.
Toto RD (2010) Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 19:444–449PubMedCrossRef
2.
Bhattacharjee R, Filler G (2002) Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol 17:302–3044PubMedCrossRef
3.
Jacobsen P, Andersen S, Jensen BR, Parving HH (2003) Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992–999PubMedCrossRef
4.
Locatelli F, Del Vecchio L, Cavalli A (2009) Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract 113:c286–c293PubMedCrossRef
5.
Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8:529–535PubMedCrossRef
6.
ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650PubMedCrossRef
7.
McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVE Pilot Study Investigators. Circulation 100:1056–1064PubMed
8.
Biswas KB, Nabi AN, Arai Y, Nakagawa T, Ebihara A, Ichihara A, Watanabe T, Inagami T, Suzuki F (2010) Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens Res 33:1053–1059PubMed
9.
Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, Itoh H (2010) New approaches to blockade of the renin–angiotensin–aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren. J Pharmacol Sci 113:296–300PubMedCrossRef
10.
Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH (2009) Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32:1873–1879PubMedCrossRef
11.
Ferrario CM (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci 86:289–299PubMedCrossRef
12.
Filler G, Priem F, Lepage N, Sinha P, Vollmer I, Clark H, Keely E, Matzinger M, Akbari A, Althaus H, Jung K (2002) Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 48:729–736PubMed
13.
Filler G, Lepage N (2003) Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 18:981–985PubMedCrossRef
14.
Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J (2008) Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 24:1039–1047PubMedCrossRef
15.
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370:221–229PubMedCrossRef
16.
Düsing R, Sellers F (2009) ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 25:2287–2301PubMedCrossRef
Metadata
Title
Are we ready to use aliskiren in children?
Authors
Erin Elizabeth Kelland
Leanne Michelle McAuley
Guido Filler
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 3/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-010-1702-z

Other articles of this Issue 3/2011

Pediatric Nephrology 3/2011 Go to the issue

Review

Genetics of congenital anomalies of the kidney and urinary tract

Original Article

Hepatic and pulmonary nodular lesions in pediatric urinary tract infections

Original Article

Expression and function of the Ets transcription factor pea3 during formation of zebrafish pronephros

Editorial Commentary

Residual renal function assessment with cystatin C

Original Article

Serum cystatin C for estimation of residual renal function in children on peritoneal dialysis

Review

PPARγ and chronic kidney disease